Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
IPSEN SA S/ADR (IPSEY)
NASDAQ:AMEX Investor Relations:
ipsen.com/investors
Company Research
Source: Business Wire
- Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases SAN DIEGO--(BUSINESS WIRE)--Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, today announced a global collaboration and option agreement with Ipsen (Euronext: IPN; ADR: IPSEY) to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder.Under the terms of the agreement, Ipsen has obtained an exclusive option to license the program globally following successful drug candidate nomination. Upon exercise of the option, Ipsen would assume responsibility for global development and commercialization.“We are delighted to join forces with Origami whose pioneering work in developing protein degraders targeting genetic neurodegenerative diseases represents a powerful new frontier in rare neuroscience,” said
Show less
Read more
Impact Snapshot
Event Time:
IPSEY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSEY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSEY alerts
High impacting IPSEN SA S/ADR news events
Weekly update
A roundup of the hottest topics
IPSEY
News
- Ipsen nominates Peter Guenter to its Board of DirectorsGlobeNewswire
- Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership TeamGlobeNewswire
- Arbitration tribunal upholds Ipsen’s termination of R&D agreement with GaldermaGlobeNewswire
- U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid LeukemiaGlobeNewswire
- IPSEN (OTCMKTS:IPSEY) was downgraded by analysts at UBS Group AG to a "neutral" rating.MarketBeat